Novo Nordisk’s $9 B Bid for Metsera Marks Sharp Shift in Obesity-Drug Strategy
Novo Nordisk has launched a surprise $9 billion (£7.1 billion) bid to acquire Metsera, upending an earlier deal with Pfizer and signalling a major strategic push into the obesity drug market. Under its new leadership, Novo’s urgent move shows the Danish drugmaker is now adopting a more aggressive posture after losing ground to Eli Lilly…